CONTRATOS DE INVESTIGACIÓN

Contrato 149/2019

Protocol title:a phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.

Financiador: GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

Duración del 08 de marzo de 2019 al 28 de febrero de 2020 (12 meses)

De ámbito Internacional (no UE). Se ha otorgado en régimen de Concesión directa.

Responsable